Guided Tissue Regeneration, Resorbable Barrier, Per Site Template

Guided tissue regeneration - resorbable barrier, per site.

RMH: Medical history reviewed/updates
Vitals: BP/pulse; other vitals if indicated

Tooth: #Tooth number(s)
Defect type: Defect type

Consent: Consent/PARQ reviewed; signed/verbally obtained

Periodontal chart/radiographs: Probing/BOP/CAL and radiographs/photos as applicable

Anesthesia: Anesthetic used
Carps: Carpules/amount

Defect documentation: Tooth/site, defect type, radiographs, intraoral photo of bony defect
Regenerative materials: Graft/biologic/membrane material and amount
Closure/prognosis: Closure method and expected follow-up

Procedure:
Incisions made.
Full thickness flap elevated.
Defect debrided.
Root surface conditioned.
Bone graft placed: Graft material/amount
Resorbable membrane placed: Resorbable membrane placed
Membrane secured.
Flap repositioned for primary closure.
Sutured with: Suture material/size
Hemostasis achieved.

Complications: None or describe.

Patient tolerance: Tolerance/response.

Post-op instructions: Instructions reviewed.
Rx: Prescription or none

NV: Next visit

Documentation requirements

Periodontal regenerative notes are reviewed more aggressively than almost any other perio code — fees are high, the procedure is elective relative to extraction, and carriers want proof that the defect was a regenerative candidate, not just a deep pocket. Per AAP Best Evidence Consensus on regeneration's periodontics chapter, a defensible D4266 note must contain:

• Tooth and site — universal numbering, specific surface (M/D/B/L) or furcation entrance (B/L for mandibular molars; B/MP/DP for maxillary molars). One D4266 line per anatomic site. "Quadrant" or "arch" is not a billable site.
• Defect type and morphology — two-wall, three-wall, combined two-/three-wall, or Class II furcation (B / L / MP / DP). Include defect depth (mm from CEJ to base of defect or from alveolar crest to base) and width. One-wall, horizontal, and Class III furcation defects are not regenerative indications and should be re-coded if billed as D4266.
• Pre-op periodontal chart — full 6-point probing, BOP, CAL, recession, mobility (Miller I/II/III), furcation grades (Glickman or Hamp), suppuration, plaque/calculus index. The probing depth and CAL at the treated site drive the medical-necessity argument.
• Pre-op periapical or vertical bitewing of the site — diagnostic-quality, demonstrating the vertical bony defect or furcation radiolucency. CBCT (D0364-D0368) is appropriate for complex multi-defect cases or maxillary furcations and bills separately when indicated.
• Pre-op intraoral photograph of the bony defect — taken intra-operatively after flap reflection, ideally with a periodontal probe in place to demonstrate defect depth and walls. Several Medicaid MCOs and many commercial carriers require an intraoperative photograph for D4266/D4267 reimbursement; even when not strictly required, the photo is the single most valuable audit defense.
• Periodontal diagnosis and case type — AAP staging and grading: Stage III or IV (severe attachment loss with regenerative candidacy), Grade B or C (rate of progression). Localized vs generalized. The 2017 AAP/EFP classification is the current standard; pre-2017 case-type language ("Type IV periodontitis") is outdated and weak on review.
• Phase I therapy completed and re-evaluation — D4341/D4342 SRP, D4346 if indicated, OHI, and a re-evaluation (D0180 or charted re-eval) showing residual deep pocketing at the planned surgical site after non-surgical therapy. Surgical regeneration without prior non-surgical therapy is a medical-necessity denial pattern.
• Systemic and behavioral risk factors — smoking status (and cessation counseling if applicable; smoking is a relative contraindication to GTR per AAP — outcomes are reduced 30-50%), diabetes (HbA1c if known; uncontrolled diabetes reduces regenerative outcomes), bisphosphonate / anti-resorptive history (MRONJ risk for periodontal surgery), immunosuppression, oral hygiene compliance.
• Informed consent / PARQ — risks specific to regenerative surgery: post-op pain, swelling, bleeding, flap dehiscence and membrane exposure (membrane exposure significantly compromises outcomes), infection, recession, sensitivity, suboptimal regeneration, need for repeat surgery or extraction if regeneration fails, alternatives (open-flap debridement, osseous surgery, extraction with implant or no treatment). Note signed vs verbal.
• Pre-op vitals — BP and pulse pre-op; many state boards require vitals on surgical visits and many practices repeat post-op. Hypertensive patients and patients on anticoagulants warrant explicit hemostasis planning.
• Anesthesia — agent, concentration, vasoconstrictor, technique (local infiltration, block), and carpule count. Long-acting agents (bupivacaine 0.5%) are common for regenerative surgery to reduce post-op pain.
• Surgical access — incision design (sulcular, papilla-preservation flap, simplified papilla preservation, modified Widman, vertical releasing if used), full-thickness flap elevation, extent (one tooth, multiple teeth), and preservation of interproximal tissue (papilla preservation is the AAP-preferred design for regenerative surgery to maintain primary closure over the membrane).
• Defect debridement — granulation tissue removed, root surface debrided of calculus and biofilm, defect walls visualized and confirmed (re-state the wall count after direct visualization — the intraoperative finding sometimes differs from radiographic estimate).
• Root surface conditioning — agent if used (citric acid, EDTA, tetracycline) or "mechanical debridement only." EDTA gel (24%, 2 min) is the most common contemporary conditioner; tetracycline conditioning is described in older literature and less common today. Some carriers ask about conditioning specifically.
• Bone graft (if placed) — material (autograft, allograft DFDBA/FDBA, xenograft Bio-Oss / Cerabone, alloplast — beta-TCP, bioactive glass), volume in cc or mg, and lot number if recorded. Bill separately as D4263 (first site) and/or D4264 (each additional site) when a graft is used inside the defect under the membrane.
• Membrane material and dimensions — manufacturer and product (e.g., BioGide collagen, Cytoplast RTM Collagen, OsseoGuard, Mem-Lok), composition (porcine / bovine / equine collagen; synthetic resorbable polymer), trimmed dimensions, and confirmation that the membrane extended at least 2-3 mm beyond defect margins onto sound bone. Resorbable membrane = D4266; non-resorbable (PTFE, titanium-reinforced) = D4267.
• Biologic adjuncts (if used) — enamel matrix derivative (Emdogain) is billed separately under D4265 (biologic materials to aid in soft and osseous tissue regeneration). PRF/PRP is generally not separately billable. Document any biologic product, lot, and rationale.
• Membrane stabilization — sutures, tacks, or sling sutures used to stabilize the membrane against the root and bone. Mobile membrane = compromised regeneration.
• Flap closure — primary closure tension-free over the membrane is the AAP-preferred standard. Suture material and size (e.g., 5-0 PTFE, 5-0 chromic gut, 6-0 polypropylene), suture technique (interrupted, sling, modified mattress, vertical mattress), suture count.
• Hemostasis — confirmed; method if anything beyond pressure (electrocautery, hemostatic agent, additional sutures).
• Complications — explicit "None" or describe (membrane exposure during placement, flap perforation, excessive bleeding, hemodynamic event).
• Patient tolerance / response — tolerated well, mild discomfort managed, etc. Note post-op vitals if extended visit.
• Post-op instructions — soft diet, no brushing/flossing of surgical site for 2-4 weeks (chlorhexidine 0.12% rinse 2x daily as substitute), no chewing on the surgical side, no strenuous activity for 48-72 h, no smoking (critical — emphasize), return precautions for excessive bleeding / swelling / fever / membrane exposure / suture loss, importance of follow-up visits.
• Prescriptions — analgesic regimen (NSAID + acetaminophen layered is the contemporary AAP-preferred analgesic strategy; opioids reserved for breakthrough), antimicrobial mouthrinse (chlorhexidine 0.12%), and antibiotic if indicated (systemic antibiotic is debated — some AAP-cited regenerative protocols use 7-10 days amoxicillin or amoxicillin+metronidazole peri-operatively, others rely on local conditions; document the rationale either way).
• Next visit — suture removal at 10-14 days (or note resorbable sutures); 1-month, 3-month, and 6-month re-evaluations are typical for regenerative cases; re-probing is deferred until at least 6 months post-op to avoid disrupting the maturing wound.
• Provider signature and assistant initials — required.

Two phrases that defuse the most common medical-necessity denials: an explicit defect-morphology line ("two-wall infrabony defect mesial #19, 7 mm depth, three walls visualized intra-operatively after debridement") and a residual-pocketing line linking the surgery to documented Phase I therapy ("Phase I SRP completed 2026-01-15 quadrants UR/UL/LR/LL; re-eval 2026-03-08 demonstrated residual 8 mm pocket M #19 with BOP, CAL 7 mm").

Common denial reasons

D4266 is one of the highest-scrutiny perio codes — high fee, elective relative to extraction, defect-specific medical-necessity criteria, and a long history of carrier audits citing inappropriate billing on non-regenerative defects. The most frequent reasons it is denied, downgraded, or recouped:

• Defect not a regenerative candidate — one-wall defect, horizontal bone loss, Class III furcation, or generalized severe horizontal loss billed as D4266. AAP regeneration consensus and most carrier policies recognize two-/three-wall infrabony defects and Class II furcations (mandibular more predictable than maxillary) as the GTR indications. Other defect morphologies are denied on medical-necessity grounds.
• Missing intraoperative photograph of the bony defect — many Medicaid MCOs and several commercial carriers explicitly require this for D4266 reimbursement. Even when not strictly required, the photo is the single most valuable audit defense, and its absence is a frequent recoupment basis.
• Missing pre-op radiograph showing the vertical defect — diagnostic-quality PA or vertical bitewing demonstrating the defect is required. Horizontal-only bone loss radiographs do not support GTR.
• Phase I therapy not documented or not completed — surgical regeneration without prior SRP and re-evaluation showing residual disease is denied as premature. The chart must show the SRP date, the re-evaluation, and the residual pocketing at the surgical site.
• AAP staging/grading missing or pre-2017 case-type language — "Type IV periodontitis" or no AAP classification at all reads as outdated documentation. Stage III or IV with Grade B or C is the contemporary supporting language.
• Tooth-history conflict — prior D4266 / D4267 on the same site within the carrier's lookback window. Most plans will not pay regenerative surgery on a previously regenerated site within 24-60 months.
• Wrong membrane code (D4266 vs D4267) — resorbable vs non-resorbable membrane; the codes are not interchangeable. Auto-rejected on documentation review when the chart names a non-resorbable PTFE/titanium-reinforced membrane on a D4266 claim.
• D4266 billed for ridge preservation / socket grafting / implant GBR — those are D7953 / D6104, not D4266. Auto-rejected when the chart says "post-extraction" or "implant site."
• Smoker without cessation counseling documented — some carriers (and most MCO regenerative policies) explicitly cite smoking as a relative contraindication and require documented cessation counseling. Outcomes literature supports the policy; AAP regeneration consensus reports 30-50% reduction in regenerative outcomes in active smokers.
• Same-site same-DOS conflict with D4267 — mutually exclusive; pick one membrane class.
• Same-day SRP (D4341/D4342) on the regenerative tooth — bundles into the surgery; SRP must precede on a separate DOS and the re-evaluation must show residual disease.
• No prior authorization where required — most commercial plans and almost all Medicaid MCOs require pre-D for regenerative codes; submitting D4266 without prior auth is a routine denial.
• Maxillary Class III or proximal furcation billed as D4266 — Class III furcations are not recognized regenerative indications. Maxillary proximal furcations (mesial-palatal, distal-palatal) have low predictability per AAP and are frequently denied.
• Hopeless-prognosis tooth — chart lists tooth as Mobility III, severe attachment loss, or borderline candidate for extraction; carriers deny GTR on hopeless teeth as not medically necessary, recommending extraction with future implant or bridge instead.
• Default-template chart notes — identical defect morphology, materials, and post-op language across multiple patients flagged as templated. Site-specific defect descriptions and photo documentation defeat this audit pattern.
• Missing membrane manufacturer / lot information — chart says "membrane placed" with no product identity. Some carriers request the product on review and will deny without it.
• Missing primary closure documentation — flap closure tension-free over the membrane is the AAP-preferred standard; charts that don't document closure quality face follow-up questions if the case fails or the patient develops a post-op exposure.
• Restorative or implant code billed on the same tooth shortly after — if the same tooth is extracted and implanted within 6-12 months of D4266, carriers may seek recoupment on the basis that regeneration was not medically necessary. Documenting the patient's election to escalate to extraction (vs treatment failure) is the defense.

Related templates